EGFR and non-small cell lung carcinoma: Baseline brain metastasis occurred in about 10% of the NSCLC patients,2,3 and about 20%-30% of patients with NSCLC developed brain metastasis during treatment.4-6 The efficacy of different EGFR-TKIs in treating patients with brain metastasis should be further explored as the prognosis of patients with brain metastasis was rather poor.